BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
A Phase II/III, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Two Different Dose Regimens of BI 655066 (Risankizumab) and Placebo and Maintenance of Response of BI 655066 (Risankizumab) Administered Subcutaneously in Japanese Patients With Moderate to Severe Chronic Plaque Type Psoriasis.
Sponsor: AbbVie
This PHASE2 trial investigates Psoriasis and is currently completed. AbbVie leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Sep 2018 — Mar 2019 [monthly]
Completed PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
May 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.